Q-omics provides the consensus-scored C11orf98 profile across patient tissues and cancer cell-line models. C11orf98 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C11orf98 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, C11orf98 RNA expression shows 18,126 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where C11orf98 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf98 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf98 survival associations across molecular data types. C11orf98 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf98 RNA expression–survival associations across cancer types. High C11orf98 expression shows unfavorable associations in KIRC, ACC, KICH, LIHC and UVM, but favorable associations in THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C11orf98 RNA expression.
This table summarizes C11orf98 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C11orf98. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf98 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, LIHC, LUAD and STAD. The BLCA box plot shows higher C11orf98 RNA expression in tumor versus normal tissue (log2 FC = +1.084, t-test p < 0.001).
This table shows molecular features associated with C11orf98 in patient tissues and cancer cell lines. In patient samples, C11orf98 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf98 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
